Siltartoxatug clinical trials
Also written TNM002.
How each study uses siltartoxatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TNM002
- 3
Studies by the year they started
5 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Zhuhai Trinomab Pharmaceutical Co., Ltd. (5)
Studies
Open first, then newest update. How each study uses siltartoxatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against TetanusCompletedPhase 3Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT05664750Written as TNM002
- Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult VolunteersCompletedPhase 2Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT05625477Written as TNM002 (low dose)
- A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus VaccineCompletedPhase 1Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT06607380Written as TNM002
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy AdultsCompletedPhase 1Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT05842798Written as TNM002
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy AdultsCompletedPhase 1Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT04629131Written as TNM002 Dosage 1 (10 μg/kg)
Codes
What other systems call siltartoxatug · ClinicalTrials.gg INT016424
- UNII (FDA) E6R33YNF4LSILTARTOXATUGOne source FDA
- NCI Thesaurus C206988SiltartoxatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E6R33YNF4L | SILTARTOXATUG | One source FDA |
| NCI Thesaurus | C206988 | Siltartoxatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.